2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

ASH 2024 Insights: Odronextamab in R/R DLBCL Post-CAR T-Cell Progres…

2024 ASH Annual Meeting Insights Hub

M. Matasar

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Tandem 2025 Insights: Real-World Evidence Study Assessing Efficacy a…

Insights from 2025 Tandem Annual Meeting

G. Shouse

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

DLBCL: Treatment Options for Transplant-Ineligible Patients

Amit Mehta

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Standards of Care and Future Directions in FL

Martin Dreyling

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray